Three related reactions in three countries
The US label’s main table only includes reactions seen in at least 5% of people, so these three sit in a sentence underneath it; the data come from the two placebo-controlled trials the label calls Trial 1 and Trial 6 [1]. Canada prints them in its table, which uses a 1% threshold and calls the trials PIONEER 1 and PIONEER 8 [3]. Europe gives frequency classes [2].
| Reaction | US PI, section 6.1 [1] | Canadian PM, Table 3 [3] | EU SmPC 4.8 [2] |
|---|---|---|---|
| Reflux disease (GERD) | 0.3% / 2% / 2% | 0.3% / 1.7% / 2.2% | Common |
| Indigestion (dyspepsia) | 0.6% / 3% / 0.6% | 0.6% / 3.1% / 0.6% | Common |
| Gastritis | 0.8% / 2% / 2% | 0.8% / 1.7% / 1.7% | Common |
| Delayed stomach emptying | Not tabulated | After approval | Uncommon |
Reading percentages this small
Reflux disease and gastritis behave alike: about 2 in 100 people on either strength, fewer than 1 in 100 on placebo [1]. Indigestion is the odd one: 3% on 7 mg but only 0.6% on 14 mg, the same as placebo [1]. With roughly 356 people per group, two or three people either way can shift a figure, and the label offers no explanation.
These are counts of people who reported the reaction at least once. The labels do not say how long heartburn lasted or whether it eased with time.
What larger studies add
A 2025 meta-analysis pooled 55 placebo-controlled randomised trials of GLP-1 medicines with 106,395 participants. It concluded that these medicines probably increase the risk of reflux disease, with a risk ratio of 2.19, or about 4 more cases per 1,000 people [4]. The rise looked larger in weight-loss trials and with higher doses, but those subgroup differences were not statistically significant [4].
Patient voices point the same way, with the usual limits. In a 2024 study of online reviews covering both tablet and injected semaglutide, reflux was mentioned 29 times and heartburn 24 times [5]. Reviews come from people who choose to post and cannot show how often heartburn happens [5].
Why the tablet might bring on heartburn
- Supported by the labels: semaglutide delays early emptying of the stomach after meals [1], and Europe lists delayed stomach emptying itself as an uncommon reaction [2].
- Proposed, not measured for Rybelsus®: MedlinePlus explains that heartburn happens when the muscle band at the bottom of the food pipe lets stomach contents back up, and that a full stomach pressing on it makes reflux easier [6]. Whether slower emptying does this on Rybelsus® has not been studied directly.
- General: the meta-analysis found reflux risk across GLP-1 medicines as a class [4], so this is not something unique to the oral form.
The tablet, stomach conditions and acid remedies
Rybelsus® is absorbed mainly in the stomach [1], so people with an existing stomach problem often ask whether it still works. The US label reports no clinically significant change in semaglutide levels in people with chronic gastritis or reflux disease, and none when the tablets were taken with omeprazole [1]. Europe also found no relevant change with omeprazole [2]. These findings concern blood levels, not whether heartburn improves.
Antacids, acid blockers and other remedies taken by mouth still have to wait at least 30 minutes after the tablet, which is swallowed with plain water only [1]. Because semaglutide slows stomach emptying, it can also affect how other oral medicines are absorbed [1]. List every heartburn product for your pharmacist and prescriber.
Other triggers, and self-care
MedlinePlus names a hiatal hernia, pregnancy and several medicines as causes of heartburn, including beta-blockers and calcium channel blockers for blood pressure or heart disease, sedatives, some asthma medicines and tricyclic antidepressants [6]. These are common in people with diabetes and heart risk: in Trial 7, 64% of participants were on a beta-blocker [1].
To prevent heartburn, MedlinePlus suggests avoiding trigger foods and drinks such as alcohol, caffeine, fizzy drinks, chocolate, citrus, mint, tomato and spicy or fatty food; eating smaller meals; not bending over or exercising right after eating; not eating in the 3 to 4 hours before bed; loose clothing around the waist; raising the head of the bed; and not smoking [6]. It lists antacids, H2 blockers and proton pump inhibitors as over-the-counter options if that is not enough [6]. Ask a pharmacist which suits you.
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Burning with squeezing, crushing or pressing chest pain
Contact: Emergency services (911): it may be a heart attack
MedlinePlus [6]
- Vomit that is bloody or looks like coffee grounds, or black or maroon stools
Contact: Urgent medical care
MedlinePlus [6]
- Severe upper-stomach pain that does not go away, sometimes through to the back
Contact: Stop Rybelsus® and call your provider right away
Rybelsus® Medication Guide [1]
Today
At your next appointment
- Heartburn that is frequent, lasts weeks despite self-care, or gets worse with remedies
Contact: Your provider at a planned visit
MedlinePlus [6]